secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2026-03-06T23:59:59+00:00
Accession:  0000879169-26-000013
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues Complete Response Letter for Incyte's Zynyz in NSCLC due to facility inspection findings
--------------------------------------------------------------------------------

- FDA CRL for Zynyz (retifanlimab) sBLA for metastatic NSCLC with platinum chemo, citing Catalent Indiana inspection findings.
- CRL did not cite efficacy or safety concerns; Zynyz's data from Phase 3 POD1UM-304 trial remains positive.
- Incyte working with FDA and Catalent Indiana to address CRL and support potential sBLA resubmission.
- The inspection findings at Catalent Indiana (part of Novo Nordisk) are not specific to Zynyz.
- No other approvability issues raised; drug substance manufacturer not a concern.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916926000013/0000879169-26-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916926000013/incy-20260227.htm
  HTML page:      https://secwatch.observer/filing/0000879169-26-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer